Redirecting to https://investors.bms.com/iframes/press-releases/press-release-details/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx...

Click here if your browser doesn't automatically take you to this page.